Acquired EGFR resistance mutation C797S in pancreatic adenocarcinoma following partial response to third-generation EGFR inhibitor therapy.

Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/52274

Title:	Acquired EGFR resistance mutation C797S in pancreatic adenocarcinoma following partial response to third-generation EGFR inhibitor therapy.
Authors:	Papa B.;Dorwal P.;Htain P.;Robin J.;Tan C.P.;Singhal N.
Monash Health Department(s):	Pathology Genetics
Institution:	(Papa, Dorwal) Department of Anatomical Pathology, Monash Health, Melbourne, Australia (Dorwal, Htain, Robin) Diagnostic Genomics, Monash Health, Melbourne, Australia (Dorwal) School of Clinical Sciences, Monash University, Melbourne, Australia (Tan, Singhal) Cancer Centre, Royal Adelaide Hospital, School of Medicine, University of Adelaide, SA, Australia
Issue Date:	10-Aug-2024
Copyright year:	2024
Publisher:	Lippincott Williams and Wilkins
Place of publication:	United States
Publication information:	JCO Precision Oncology. 8(no pagination), 2024. Article Number: e2400132. Date of Publication: 01 Jul 2024.
Journal:	JCO Precision Oncology
DOI:	http://monash.idm.oclc.org/login?url=https://dx.doi.org/10.1200/PO.24.00132
PubMed URL:	39074344 [https://www.ncbi.nlm.nih.gov/pubmed/?term=39074344]
URI:	https://repository.monashhealth.org/monashhealthjspui/handle/1/52274
Type:	Article
Subjects:	adjuvant chemotherapy cancer palliative therapy clinical computer assisted tomography histopathology liver metastasis neoadjuvant chemotherapy pancreas adenocarcinoma
Appears in Collections:	Articles

48

checked on Jun 3, 2025

Check